Veravas, Inc.
  1. Companies
  2. Veravas, Inc.
  3. Products
  4. VeraPrep ABAS - Heterophilic Antibodies

VeraPrep ABASHeterophilic Antibodies

SHARE
Remove anti-biotin and anti-streptavidin from samples before it interferes with results. While the issue and risk of free biotin interference in immunoassays are more recognized and understood, the threat of interferences by anti-biotin and anti-streptavidin (ABAS) heterophilic antibodies may be underestimated and can also cause erroneous results.
Most popular related searches

Although the cause of anti-streptavidin antibodies is not fully known and under debate, one possible cause could be from the bacterium S. avidinii. It is thought that many people are exposed to these bacteria in daily life and could develop an immunological reaction to it. The body can create anti-biotin antibodies as a result of high circulating biotin levels often found in patients taking over the counter biotin supplements or high-dose biotin therapy. Unfortunately, ABAS antibodies can interfere with certain lab tests and cause incorrect results. Similar to biotin interference, ABAS interference falsely decreases test signal which can result in a false high or low test result depending on the assay format.

To mitigate this growing problem, Veravas has created a novel product that does not bind free biotin but can specifically detect and remove both anti-streptavidin and anti-biotin interference from the same sample and improve confidence in test results.

  • Simple, 15-minute protocol
  • Uses serum or plasma
  • Uses a strong VeraMag™ magnet to capture and remove anti- biotin and/or anti-streptavidin interference
  • No sample dilution
  • No sample dilution
  • No centrifugation necessary
  • May reduce number of send outs
  • Shorter turnaround time than current methods
  • Reagent designed so it doesn’t alter the sample (No matrix effect)
  • When you suspect anti-streptavidin and/or anti-biotin interference
  • High risk of anti-biotin interference (e.g. chronic high-dose biotin supplementation or therapy, renal disease, autoimmune disease, etc)
  • If there is known heterophilic antibody interference in the sample
  • Use with VeraPrep Biotin to determine if anti-biotin, biotin, and/or anti-streptavidin interference mechanisms are present

VeraPrep ABAS treatment of the baseline PTH sample demonstrated reagent neutrality and no matrix effect as PTH results only differed by 1.3%. When 250 ng/mL free biotin, 16.5 µg anti-biotin IgG, 16.5 µg anti-streptavidin IgG, or a 50/50 mix of 8.25 µg anti-biotin IgG and 8.25 µg anti-streptavidin IgG, were spiked into the PTH baseline sample they significantly interfered with the streptavidin/biotin-based PTH ELISA assay by decreasing PTH results by 74 to 97%. VeraPrep ABAS treatment successfully removed the anti-biotin IgG and anti-streptavidin IgG interference by increasing the PTH results from 253% to 3546%, or from -1.5% to -9.9% of baseline. However, when the free biotin spike was treated with VeraPrep ABAS the PTH result did not significantly change and was only -2.3% different. This is expected as VeraPrep ABAS does not bind or remove free biotin.